bs_bs_banner
Clinical and Experimental Immunology
I M M U N O M O D U L AT I O N
doi:10.1111/cei.12537
7th International Immunoglobulin Conference: Immunomodulation
M. G. Danieli* and Y. Shoenfeld† *Università Politecnica delle Marche, Ancona, Italy, and †Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Correspondence: M. G. Danieli. E-mail: [email protected]
Summary Rheumatoid arthritis (RA) is a debilitating autoimmune disease that is usually treated aggressively to slow the rate of joint destruction. The therapeutic strategy used at the French centre, described here, is to use the nonbiological disease-modifying drug, methotrexate, as first-line therapy and to add biological agents as second-line treatment. The two other autoimmune diseases discussed in this session were immunobullous skin diseases, and secondary recurrent miscarriage (RM). In the former conditions, low levels of pathogenic autoantibodies can be achieved with adjuvant intravenous immunoglobulin (IVIg) therapy, usually in combination with an immunosuppressant. Secondary RM has an autoimmune basis, as shown by high tumour necrosis factor (TNF)-α levels and specific human leucocyte antigen (HLA) polymorphisms. Although the mechanism is not yet known, IVIg may also be an effective treatment, despite the generally low doses used in published studies.
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 178: 123
123
This document is a scanned copy of a printed document. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material.
Clinical and Experimental Immunology
I M M U N O M O D U L AT I O N
doi:10.1111/cei.12537
7th International Immunoglobulin Conference: Immunomodulation
M. G. Danieli* and Y. Shoenfeld† *Università Politecnica delle Marche, Ancona, Italy, and †Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Correspondence: M. G. Danieli. E-mail: [email protected]
Summary Rheumatoid arthritis (RA) is a debilitating autoimmune disease that is usually treated aggressively to slow the rate of joint destruction. The therapeutic strategy used at the French centre, described here, is to use the nonbiological disease-modifying drug, methotrexate, as first-line therapy and to add biological agents as second-line treatment. The two other autoimmune diseases discussed in this session were immunobullous skin diseases, and secondary recurrent miscarriage (RM). In the former conditions, low levels of pathogenic autoantibodies can be achieved with adjuvant intravenous immunoglobulin (IVIg) therapy, usually in combination with an immunosuppressant. Secondary RM has an autoimmune basis, as shown by high tumour necrosis factor (TNF)-α levels and specific human leucocyte antigen (HLA) polymorphisms. Although the mechanism is not yet known, IVIg may also be an effective treatment, despite the generally low doses used in published studies.
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 178: 123
123
This document is a scanned copy of a printed document. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material.
